Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective

  • Andrea Gramegna (Creator)
  • Giovanni Sotgiu (Creator)
  • Marta Di Pasquale (Contributor)
  • Dejan Radovanovic (Creator)
  • Silvia Terraneo (Creator)
  • L. F. Reyes (Creator)
  • Ester Vendrell (Creator)
  • J. Neves (Contributor)
  • Francesco Menzella (Creator)
  • Francesco Blasi (Creator)
  • Stefano Aliberti (Creator)
  • Marcos Restrepo (Creator)



Abstract Background Empirical antibiotic coverage for atypical pathogens in community-acquired pneumonia (CAP) has long been debated, mainly because of a lack of epidemiological data. We aimed to assess both testing for atypical pathogens and their prevalence in hospitalized patients with CAP worldwide, especially in relation with disease severity. Methods A secondary analysis of the GLIMP database, an international, multicentre, point-prevalence study of adult patients admitted for CAP in 222 hospitals across 6 continents in 2015, was performed. The study evaluated frequency of testing for atypical pathogens, including L. pneumophila, M. pneumoniae, C. pneumoniae, and their prevalence. Risk factors for testing and prevalence for atypical pathogens were assessed through univariate analysis. Results Among 3702 CAP patients 1250 (33.8%) underwent at least one test for atypical pathogens. Testing varies greatly among countries and its frequency was higher in Europe than elsewhere (46.0% vs. 12.7%, respectively, p 
Date made available2018

Cite this